Drug Type Small molecule drug |
Synonyms Balapiravir, Balapiravir hydrochloride (USAN), R-1626 + [3] |
Target |
Mechanism NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H31ClN6O8 |
InChIKeyRAJFQMDUVDHLII-PYZPAVLJSA-N |
CAS Registry690270-65-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1 | Phase 2 | US | 01 Dec 2007 | |
Chronic hepatitis C genotype 1 | Phase 2 | AU | 01 Dec 2007 | |
Chronic hepatitis C genotype 1 | Phase 2 | AT | 01 Dec 2007 | |
Chronic hepatitis C genotype 1 | Phase 2 | CA | 01 Dec 2007 | |
Chronic hepatitis C genotype 1 | Phase 2 | FR | 01 Dec 2007 | |
Chronic hepatitis C genotype 1 | Phase 2 | DE | 01 Dec 2007 | |
Chronic hepatitis C genotype 1 | Phase 2 | IT | 01 Dec 2007 | |
Chronic hepatitis C genotype 1 | Phase 2 | PR | 01 Dec 2007 | |
Chronic hepatitis C genotype 1 | Phase 2 | ES | 01 Dec 2007 | |
Elliptocytosis, Hereditary | Phase 2 | US | 01 Dec 2007 |